Therapeutic Potential of Peroxisome Proliferator-Activated Receptor Modulation in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis

Nuclear Receptor Research
doi 10.11131/2017/101310
Full Text
Abstract

Available in full text

Date
Authors
Publisher

KenzPub

Related search

Global Perspectives on Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis

Hepatology
MedicineHepatology
2019English

Tanshinone IIA Ameliorates Non-Alcoholic Fatty Liver Disease Through Targeting Peroxisome Proliferator-Activated Receptor Gamma and Toll-Like Receptor 4

Journal of International Medical Research
BiochemistryMedicineCell Biology
2019English

Portal Lymphadenopathy Predicts Non-Alcoholic Steatohepatitis and Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease

PLoS ONE
Multidisciplinary
2018English

1. Fatty Liver and Non-Alcoholic Steatohepatitis

Internal Medicine
Internal MedicineMedicine
2007English

Systematic Review: The Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2010English

Pathogenesis of Non-Alcoholic Steatohepatitis and Its Potential Therapeutic Strategies

2015English

Patient-Reported Outcomes and the Economic Effects of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis - The Value Proposition

Hepatology
MedicineHepatology
2018English

Non-Alcoholic Fatty Liver Disease and Disease Mongering

American Journal of Medicine
Medicine
2019English

Treatment of Non-Alcoholic Fatty Liver Disease

Postgraduate Medical Journal
Medicine
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy